Cargando…
Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer
Bladder cancer is considered as primarily a disease of the elderly, typically aged in their 70s or 80s and often with associated medical comorbidities. Unfortunately, fewer elderly patients receive radical treatment for muscle-invasive bladder cancer (MIBC) that their younger counterparts. Over the...
Autores principales: | Turgeon, Guy-Anne, Souhami, Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122205/ https://www.ncbi.nlm.nih.gov/pubmed/25140295 http://dx.doi.org/10.3389/fonc.2014.00206 |
Ejemplares similares
-
Single Institutional Experience of Bladder-Preserving Trimodality Treatment for Muscle-Invasive Bladder Cancer
por: Joung, Jae Young, et al.
Publicado: (2008) -
Trimodal Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Meta-Analysis
por: Ding, Hui, et al.
Publicado: (2020) -
Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer
por: Bachir, Bassel G., et al.
Publicado: (2017) -
Evaluation of Survival Outcomes With Trimodal Therapy as Primary Therapy for Non-organ-confined Bladder Cancer
por: Guo, Yadong, et al.
Publicado: (2019) -
Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)